国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
9期
1590-1593
,共4页
更昔洛韦%阿昔洛韦%单纯疱疹病毒性角膜炎%系统评价
更昔洛韋%阿昔洛韋%單純皰疹病毒性角膜炎%繫統評價
경석락위%아석락위%단순포진병독성각막염%계통평개
ganciclovir%acyclovir%herpes simplex virus keratitis%systematic reviews
目的：评价更昔洛韦治疗单纯疱疹性角膜炎的疗效和安全性。<br> 方法：计算机检索 Cochrane Library、EMbase、PubMed、中国生物医学数据库、中国期刊全文数据库、维普数据库和万方数据库,收集所有更昔洛韦对比阿昔洛韦治疗单纯疱疹病毒性角膜炎的随机对照试验,由两名评价员独立筛选合格文献并提取相关信息进行分析。根据 Cochrane 协作网推荐的工具进行偏倚风险评估,用 Revman 5.0软件进行统计学分析。<br> 结果：最终纳入14个随机对照试验,共4820例单纯疱疹病毒性角膜炎患者。按以患者人数为观察对象和以患眼数为观察对象分组分析,并对纳入研究根据随访时间进行亚组分析。更昔洛韦组在有效率、复发率等方面优于阿昔洛韦组,差异具有统计学意义[RR =1.22,95% CI (1.10~1.36)； OR =4.50,95% CI (2.02~10.04)； RR =0.23,95% CI (0.10~0.52)]。更昔洛韦组不良反应发生率比阿昔洛韦组少,差异具有统计学意义[ RR =0.12,95% CI (0.03~0.46)]。两组的不良反应均可自行缓解。<br> 结论：目前证据表明,更昔洛韦相比阿昔洛韦治疗单纯疱疹病毒性角膜炎疗效好、安全性高。
目的：評價更昔洛韋治療單純皰疹性角膜炎的療效和安全性。<br> 方法：計算機檢索 Cochrane Library、EMbase、PubMed、中國生物醫學數據庫、中國期刊全文數據庫、維普數據庫和萬方數據庫,收集所有更昔洛韋對比阿昔洛韋治療單純皰疹病毒性角膜炎的隨機對照試驗,由兩名評價員獨立篩選閤格文獻併提取相關信息進行分析。根據 Cochrane 協作網推薦的工具進行偏倚風險評估,用 Revman 5.0軟件進行統計學分析。<br> 結果：最終納入14箇隨機對照試驗,共4820例單純皰疹病毒性角膜炎患者。按以患者人數為觀察對象和以患眼數為觀察對象分組分析,併對納入研究根據隨訪時間進行亞組分析。更昔洛韋組在有效率、複髮率等方麵優于阿昔洛韋組,差異具有統計學意義[RR =1.22,95% CI (1.10~1.36)； OR =4.50,95% CI (2.02~10.04)； RR =0.23,95% CI (0.10~0.52)]。更昔洛韋組不良反應髮生率比阿昔洛韋組少,差異具有統計學意義[ RR =0.12,95% CI (0.03~0.46)]。兩組的不良反應均可自行緩解。<br> 結論：目前證據錶明,更昔洛韋相比阿昔洛韋治療單純皰疹病毒性角膜炎療效好、安全性高。
목적：평개경석락위치료단순포진성각막염적료효화안전성。<br> 방법：계산궤검색 Cochrane Library、EMbase、PubMed、중국생물의학수거고、중국기간전문수거고、유보수거고화만방수거고,수집소유경석락위대비아석락위치료단순포진병독성각막염적수궤대조시험,유량명평개원독립사선합격문헌병제취상관신식진행분석。근거 Cochrane 협작망추천적공구진행편의풍험평고,용 Revman 5.0연건진행통계학분석。<br> 결과：최종납입14개수궤대조시험,공4820례단순포진병독성각막염환자。안이환자인수위관찰대상화이환안수위관찰대상분조분석,병대납입연구근거수방시간진행아조분석。경석락위조재유효솔、복발솔등방면우우아석락위조,차이구유통계학의의[RR =1.22,95% CI (1.10~1.36)； OR =4.50,95% CI (2.02~10.04)； RR =0.23,95% CI (0.10~0.52)]。경석락위조불량반응발생솔비아석락위조소,차이구유통계학의의[ RR =0.12,95% CI (0.03~0.46)]。량조적불량반응균가자행완해。<br> 결론：목전증거표명,경석락위상비아석락위치료단순포진병독성각막염료효호、안전성고。
To assess the efficiency and reliability safety of ganciclovir to herpes simplex virus keratitis. <br> ●METHODS: All of the randomized controlled trials for the study of ganciclovir versus acyclovir in the treatment of herpes simplex virus keratitis were collected from Cochrane Library, EMbase, PubMed, Chinese Bio -medicine Database, China Journal Full-text Database, VlP Database and WanFang Database. Then the data were extracted and evaluated by two reviewers independently. Risk of bias assessment was evaluated by a tool recommended by Cochrane Library. Revman 5. 0 software was used for statistical analysis. <br> ●RESULTS: Finally, 14 randomized controlled trials were included, 4820 patients totally. Subgroups were used according to the number of patients and diseased eyes as well as the difference of follow-up time. For and relapse rate, ganciclovir group was overmatch acyclovir group. There were statistical differences between the two groups [RR= 1. 22, 95%CI (1. 10-1. 36); OR = 4. 50, 95% CI (2. 02-10. 04); RR = 0. 23, 95% CI (0. 10-0. 52)]. Compared with acyclovir, ganciclovir had less side - effect. There were statistical differences between the two groups [RR = 0. 12, 95%CI (0. 03 - 0. 46)]. All of the side effects of the two groups can be relieved by themselves. <br> ● CONCLUSlON: Current evidence suggests that the ganciclovir is more efficient and safe than acyclovir in the treatment of herpes simplex virus keratitis.
